1. Home
  2. MREO vs RIGL Comparison

MREO vs RIGL Comparison

Compare MREO & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • RIGL
  • Stock Information
  • Founded
  • MREO 2015
  • RIGL 1996
  • Country
  • MREO United Kingdom
  • RIGL United States
  • Employees
  • MREO N/A
  • RIGL N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • MREO Health Care
  • RIGL Health Care
  • Exchange
  • MREO Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • MREO 326.1M
  • RIGL 335.5M
  • IPO Year
  • MREO N/A
  • RIGL 2000
  • Fundamental
  • Price
  • MREO $1.97
  • RIGL $29.74
  • Analyst Decision
  • MREO Strong Buy
  • RIGL Buy
  • Analyst Count
  • MREO 5
  • RIGL 5
  • Target Price
  • MREO $7.40
  • RIGL $38.20
  • AVG Volume (30 Days)
  • MREO 1.3M
  • RIGL 644.0K
  • Earning Date
  • MREO 11-11-2025
  • RIGL 11-06-2025
  • Dividend Yield
  • MREO N/A
  • RIGL N/A
  • EPS Growth
  • MREO N/A
  • RIGL N/A
  • EPS
  • MREO N/A
  • RIGL 5.43
  • Revenue
  • MREO $500,000.00
  • RIGL $267,921,000.00
  • Revenue This Year
  • MREO N/A
  • RIGL $59.93
  • Revenue Next Year
  • MREO $72.16
  • RIGL N/A
  • P/E Ratio
  • MREO N/A
  • RIGL $5.42
  • Revenue Growth
  • MREO N/A
  • RIGL 105.62
  • 52 Week Low
  • MREO $1.47
  • RIGL $13.57
  • 52 Week High
  • MREO $4.72
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • MREO 57.79
  • RIGL 40.10
  • Support Level
  • MREO $1.94
  • RIGL $27.75
  • Resistance Level
  • MREO $2.12
  • RIGL $29.46
  • Average True Range (ATR)
  • MREO 0.11
  • RIGL 1.51
  • MACD
  • MREO 0.02
  • RIGL -0.41
  • Stochastic Oscillator
  • MREO 62.65
  • RIGL 26.27

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: